Visceral metastasis is widely considered a prognostic factor for overall survival of men with metastatic castration-sensitive prostate cancer (mCSPC) and has been historically managed with androgen deprivation therapy (ADT). More recently, this therapeutic scenario has been enriched by the possibility to integrate ADT with chemotherapy or novel androgen-signalling–targeted inhibitors. In order to define the effect of chemotherapy/androgen-signalling–targeted inhibitors plus ADT, we performed a pooled analysis on patients with mCSPC and visceral metastases revealing that survival was significantly improved in patients without visceral metastasis (HR=0.64 95%CI: 0.56-0.74; p<0.01) compared with men with visceral metastases (HR=0.68; 95%CI: 0.51-0.91; p<0.01). Although several limitations do not allow to draw definitive conclusions, our analysis confirms the efficacy of chemotherapy/androgen-signalling–targeted inhibitors in combination with ADT also in mCSPC with visceral metastases. In the absence of specific randomized controlled trials, symptoms, toxicity, cost, patients’ preference and clinical experience should guide the decision to add chemotherapy or androgen receptor-targeted therapy to ADT in patients with visceral metastases from mCSPC.

Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue / Giandomenico Roviello, Roberto Petrioli, Donata Villari, Alberto D’Angelo. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - ELETTRONICO. - (2020), pp. 0-0. [10.1016/j.clgc.2020.06.001]

Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue

Giandomenico Roviello;Donata Villari;
2020

Abstract

Visceral metastasis is widely considered a prognostic factor for overall survival of men with metastatic castration-sensitive prostate cancer (mCSPC) and has been historically managed with androgen deprivation therapy (ADT). More recently, this therapeutic scenario has been enriched by the possibility to integrate ADT with chemotherapy or novel androgen-signalling–targeted inhibitors. In order to define the effect of chemotherapy/androgen-signalling–targeted inhibitors plus ADT, we performed a pooled analysis on patients with mCSPC and visceral metastases revealing that survival was significantly improved in patients without visceral metastasis (HR=0.64 95%CI: 0.56-0.74; p<0.01) compared with men with visceral metastases (HR=0.68; 95%CI: 0.51-0.91; p<0.01). Although several limitations do not allow to draw definitive conclusions, our analysis confirms the efficacy of chemotherapy/androgen-signalling–targeted inhibitors in combination with ADT also in mCSPC with visceral metastases. In the absence of specific randomized controlled trials, symptoms, toxicity, cost, patients’ preference and clinical experience should guide the decision to add chemotherapy or androgen receptor-targeted therapy to ADT in patients with visceral metastases from mCSPC.
2020
0
0
Goal 3: Good health and well-being for people
Giandomenico Roviello, Roberto Petrioli, Donata Villari, Alberto D’Angelo
File in questo prodotto:
File Dimensione Formato  
roviello2020.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 643.83 kB
Formato Adobe PDF
643.83 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1209608
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact